OrbiMed’s Cartesian Therapeutics RNAC Stock Holding History

OrbiMed’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-11,306	Closed	-$1.53M	–	175
2021 Q1	$1.53M	Sell	11,306 -6,666	-37%	-$828K	0.01%	152
2020 Q4	$1.63M	Sell	17,972 -51,824	-74%	-$4.49M	0.01%	145
2020 Q3	$5.19M	Hold	69,796	–	–	0.07%	126
2020 Q2	$5.95M	Sell	69,796 -16,666	-19%	-$1.51M	0.08%	114
2020 Q1	$6.25M	Sell	86,462 -9,507	-10%	-$918K	0.11%	99
2019 Q4	$6.85M	Hold	95,969	–	–	0.1%	91
2019 Q3	$5.04M	Hold	95,969	–	–	0.1%	93
2019 Q2	$5.15M	Hold	95,969	–	–	0.08%	111
2019 Q1	$6.82M	Buy	95,969 +43,334	+82%	+$2.75M	0.11%	98
2018 Q4	$4.2M	Sell	52,635 -3,792	-7%	-$865K	0.08%	105
2018 Q3	$26.3M	Sell	56,427 -5,000	-8%	-$2.01M	0.32%	78
2018 Q2	$24.4M	Hold	61,427	–	–	0.29%	77
2018 Q1	$18.8M	Hold	61,427	–	–	0.23%	84
2017 Q4	$18.1M	Hold	61,427	–	–	0.23%	82
2017 Q3	$33.6M	Hold	61,427	–	–	0.32%	74
2017 Q2	$36.6M	Hold	61,427	–	–	0.38%	66
2017 Q1	$26.4M	Hold	61,427	–	–	0.3%	70
2016 Q4	$31.6M	Hold	61,427	–	–	0.4%	56
2016 Q3	$26.3M	Hold	61,427	–	–	0.3%	68
2016 Q2	$25.8M	Buy	+61,427	New	+$25.8M	0.27%	68

Other funds holding RNAC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

OrbiMed's RNAC Position: Q2 2021 in Review

OrbiMed sold out of Cartesian Therapeutics (RNAC) in Q2 2021, closing a stake of 11,306 shares — an estimated $1.53M sold.

OrbiMed first reported a position in RNAC in Q2 2016 and held it in 20 quarters. The position peaked at $36.6M in Q2 2017. 101 funds tracked by Wall St. Rank hold RNAC as of Q2 2021.

OrbiMed reported no remaining Cartesian Therapeutics position as of Q2 2021 after selling out during the quarter.
OrbiMed sold 11,306 Cartesian Therapeutics shares in Q2 2021, an estimated $1.53M.
OrbiMed first reported a position in Cartesian Therapeutics in Q2 2016 and held it in 20 quarters.
OrbiMed's Cartesian Therapeutics position peaked at $36.6M in Q2 2017.
101 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2021.

Based on OrbiMed's 13F filing for Q2 2021, filed 16 Aug 2021.